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The research described in this thesis was initiated by the discovery and characterization of the
low-spin [(N4Py)FeIIIOOH]2+ intermediate (1), which was observed in the reaction of
[(N4Py)Fe(CH3CN)](ClO4)2 (2) with H2O2 (figure 1).1 The FeIIIOOH structural feature in 1 is
also found in natural systems like iron bleomycin2 and cytochrome P450,3 and 1 represented
the first example of such an intermediate for which this formulation could be established.
Figure 1. The ligand N4Py and the [(N4Py)FeIIIOOH]2+ intermediate (1).
As was mentioned in chapter 1, the primary goal of this research was to explore the chemistry
of the N4Py ligand and the corresponding iron complexes. The research focussed on two
central themes: N4Py iron complexes as enzyme models and the development of new
catalysts, based on N4Py iron complexes, that are capable of selective oxidation.
In this chapter the most important achievements of this research will be surveyed and some
suggestions for future research will be given. Furthermore, the prospects of these iron
complexes as enzyme models and oxidation catalyst will be discussed.
8.2 Catalytic Cycle
The chemistry of N4Py iron complexes was described in chapters 2, 3 and 4. Based on the
cumulative data presented in these chapters a catalytic cycle for N4Py iron catalyzed
oxidations can be compiled (scheme 1). The key intermediate in the cycle is the iron(III)
hydroperoxide species 1. It is formed from the low-spin iron(II) complex 2 in two steps, as
was demonstrated by titration of H2O2.4 First step an oxidation takes place to form a mixture
of mono and dinuclear iron(III) species, [(N4Py)FeIIIOH]2+ (3) and [{(N4Py)FeIII}2(µ-O)]4+
(4). In methanolic solution rapid ligand exchange takes place to form the methoxy complex,
[(N4Py)FeIIIOMe]2+ (5). These complexes were characterized spectroscopically and, in case
of 4 and 5, by X-ray crystallography. The second step is the reaction of 3, 4 or 5 with H2O2 to
form the purple colored intermediate 1. Resonance Raman studies showed 1 to contain an
unusually weak O-O bond, which could explain the high reactivity in catalytic oxidation.5 It














which are formed by homolysis of the O-O bond of the peroxide to give two radical type
oxidants, [(N4Py)FeIVO]2+ (6) and ·OH.6 These radical type active species can affect
hydrogen abstraction from a substrate to form an iron(III) species and a substrate radical. The
latter reacts either with O2 to give both alcohol and ketone in a Russell termination reaction,
or with 6 to afford alcohol. This homolytic pathway was proposed on the basis of chemical
evidence, with the use of various mechanistic probes.
Scheme 1. Proposed catalytic cycle for oxidation of alkanes by 2 and H2O2.
In the literature there are no precedents for hydrogen abstraction by FeIVO species, but in
heme chemistry the FeIVO moiety has been reported to be able to perform oxidative
transformations like the oxygenation of triphenylphosphine to triphenylphosphine oxide7 and
the nonstereospecific epoxidation of olefins.8 Apparently, the fact that N4Py is a neutral
ligand gives rise to the formation of a more electronegative FeIVO species, compared to the
doubly negative charged porphyrin ligands, making hydrogen abstraction from alkanes more































re-enter the catalytic cycle to give additional turnovers. This catalytic cycle is only valid for
alkanes as substrate. Using other substrates, like alkenes, alcohols or aromatic compounds the
mechanism of oxidation is probably more complex, since with these substrates other reaction
pathways, e.g. electron transfer9 or radical additions to double bonds,10 are possible.
Besides homolysis of the O-O bond the FeIIIOOH intermediate can also react with base to
form a blue colored, high-spin [(N4Py)Fe-η2-(OO)]+ intermediate (7), which does not show
any oxidation activity.11 This reaction is reversible, as the purple intermediate can be fully
reconstituted upon addition of acid. The side-on binding mode of the peroxide was
established by resonance Raman spectroscopy of 7 generated with H16O18OH. An interesting
question that arises is whether 7 is part of the pathway responsible for H2O2 decomposition
during the catalytic reactions. This would explain the relatively low yields of oxidized
products, based on H2O2.6
Support for this hypothesis comes from the observed kinetic solvent isotope effect (KSIE) on
the decomposition of 1. Monitoring the absorption of 1 at 548 nm in time demonstrated that
purple color disappeared slower in CD3OD than in CH3OH (figure 2), indicating that the
intermediate is more stable in the former. If the time that the absorption has reached half of
its original value is used as a measure for stability, a kinetic solvent isotope effect of 2.2 can
be calculated. This increased stability is not caused by slower oxidation of CD3OD compared
to CH3OH, as was indicated by the stability in CH3OD, which is approximately similar to that
in CD3OD. A KSIE of 1.8 was reported for cytochrome-P450cam in the course of O2
activation.12 This was ascribed to proton assisted heterolysis of the O-O bond of the FeOOH
intermediate.
Figure 2. Absorption of 1 at 548 nm monitored in time, at 25 °C. Solid line: CH3OH as solvent;
dashed line: CH3OD; dotted line: CD3OD.
However, this cannot be the cause for the observed KSIE since it has been demonstrated that
1 reacts via homolysis of the O-O bond,6 and this is not expected to be proton assisted or
dependent. Therefore the only reasonable explanation is that the KSIE is caused by the
slower formation of Fe(OO) (7) by FeOOD, which is formed by proton-deuterium exchange

















with the solvent, compared to FeOOH. This will be the result of the lower acidity of the
deuterated intermediate, FeOOD, compared to the protonated form 1. Hence, with one of the
decay pathways of 1 being less favorable in CD3OD and CH3OD an increased stability of the
intermediate will be observed in these solvents. Further proof for this hypothesis will have to
come from a full kinetic investigation of all the steps in the catalytic cycle and the
characterization of the decomposition products of 7.
8.3 N4Py Iron Complexes as Enzyme Model
Enzyme models were defined in chapter 1 as small synthetic active-site analogs that can be
used to obtain information about fundamental aspects of structure, reactivity and mechanism,
and are very suitable for spectroscopic study of putative reactive intermediates.13 Evaluating
the research described in this thesis it can be concluded that, based on these criteria, N4Py
iron complexes are excellent enzyme models.
It was demonstrated that N4Py iron complexes serve as structural models for iron bleomycin,
which also contains a pentadentate nitrogen ligand. Using the N4Py ligand several iron
complexes could be synthesized, including low-spin [(N4Py)FeII(CH3CN)](ClO4)2 (2), high-
spin [(N4Py)FeIICl](ClO4)2 (8), high-spin [(N4Py)FeIIIOMe](ClO4)2 (5) and the dinuclear
complex [{(N4Py)FeIII}2(µ-O)](ClO4)2 (4), and their relation could be established (vide
supra).4
More importantly, using N4Py iron complexes two iron-peroxide intermediates with
biological significance, e.g. a purple low-spin FeIII-η1-OOH and a blue high-spin FeIII-η2-
(OO) intermediate, could be characterized using UV/Vis, EPR, ES/MS and resonance Raman
spectroscopy.1,5,11 The spectroscopic signatures of these intermediates will facilitate future
characterization of such intermediates in biological systems.
Finally, some important mechanistic insights have been obtained by use of N4Py iron
complex as enzyme model. First of all, it was demonstrated that protonation of an iron-
peroxide intermediate is required for catalytic activity.11 This was already proposed on
theoretical grounds for cytochrome-P4503 and Fe-EDTA14 catalyzed oxidations, but the
results obtained with the FeIII-η1-OOH, which is active in oxidation of cyclohexane, and FeIII-
η2-(OO), which is not active, represent the first experimental proof for this hypothesis.
Furthermore, mechanistic study of oxidations catalyzed by 2, which involve a FeIII-η1-OOH
intermediate, revealed that the intermediate reacts through homolysis of the O-O bond of the
peroxide.6 This produces two radical oxidants: N4PyFeIVO and ·OH. These findings are in
contrast with the current proposal for iron bleomycin catalyzed oxidations, which involves
heterolysis of the O-O bond to produce a formally FeVO species.15 In view of the similar
reactivity of 2 and iron bleomycin, combined with the fact that they both form a low-spin
FeIII-η1-OOH intermediate, it can be hypothesized that they would also react via the same
mechanism. Therefore it is recommended that the mechanism of iron bleomycin catalyzed
oxidations should be carefully re-examined.
Conclusions and Perspectives
133
8.4 Catalytic Oxidation with [(N4Py)Fe(CH3CN)](ClO4)2
One of the advantages of enzyme models is that they can serve as the starting point for the
development of new generations of catalyst with improved reactivity, selectivity and
stability.16 Although 2 is an excellent enzyme model and is very reactive in catalytic
oxidation with H2O2 as sacrificial oxidant, it must be concluded that 2 cannot be of use in
organic synthesis. Important requirements for a catalyst that can be used in synthetic organic
chemistry are besides activity also chemo-, regio- and stereoselectivity. Due to the
involvement of oxygen radicals in the oxidation reaction catalyzed by 2 the latter condition
cannot be fulfilled.
Two approaches can be followed to overcome this. The first approach is ligand variation. A
series of penta and tetradentate ligands based on N4Py have been prepared and their
corresponding iron complexes tested in catalytic oxidation.17 This revealed that tetradentate
ligands like N3Py derivatives are very promising ligands for stereoselective oxidation of
alkanes and alkenes. The second possibility is to follow the supramolecular approach,18
which entails attachment of a recognition unit to the N4Py ligand. The N4Py ligand with a
covalently attached DNA binding moiety, e.g. an acridine, represents a successful example of
this approach.19 A considerable enhancement in efficiency in oxidative DNA cleavage
compared to the “basic” complex  2 could be observed (vide infra). It can be envisioned that
this approach also will work for catalytic oxidation of organic substrates, where substrate
specificity, chemo- and regioselectivity can be introduced by proper choice of the binding
and recognition unit. An example would be the covalent attachment of crown ethers, which
can recognize and bind ammonium compounds and carboxylic acids.20 After binding
regioselective oxidation of an alkyl or alkenyl side chain can possibly be achieved. Both
ligand variations and DNA cleavage will be discussed in more detail below.
8.5 Towards Selective Catalytic Oxidation
In chapter 5 a series of complexes of N4Py based ligands other pentadentate ligands were
discussed. Since all these complexes display the same reactivity pattern as observed for 2,
e.g. radical type chemistry,6 it can be concluded that iron complexes with pentadentate
ligands are not the catalysts of choice to achieve selectivity in catalytic oxidation.
Changing the denticity of the ligand from pentadentate to tetradentate by replacing one of the
pyridine groups by a non-coordinating group, i.e. the N3Py ligands, resulted in
stereoselective oxidation reactions.21 This included stereoselective hydroxylation of alkanes
and stereoselective epoxidation and dihydroxylation of alkenes. Especially surprising is the
fact that the N3Py-iron catalysts can be either a cis-dihydroxylation or a trans-
dihydroxylation catalyst dependent on the solvent that is used for the reaction. In acetonitrile
cis-dihydroxylation is observed as the major reaction whereas in acetone this is trans-
dihydroxylation, although the scope of the latter reaction remains to be established.
Taken together these results, combined with those obtained by other groups,22 allow the
formulation of a set of empirical guidelines for ligand design and selection of conditions for
catalytic oxidation with iron complexes using H2O2.
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(i) Activity. If the most important requirement for a catalyst is activity rather than chemo or
stereoselectivity, complexes with pentadentate ligands are preferable since these complexes
generally give an efficient reaction without the need of precautions like slow addition of
peroxide. Applications where this may be important are for example stain bleaching, for use
in detergents,23 pulp bleaching for use in the paper industry23a or wastewater treatment.23a
When desired, substrate specificity or regiospecificity might be obtained by introducing
recognition moieties into the ligand (vide infra).
(ii) Hydroxylation. Stereoselective hydroxylation of alkanes complexes can be accomplished
with iron complexes containing tetradentate ligands, in CH3CN as solvent. At this point it is
not clear if the location of the two open coordination sites on the metal is important, i.e.
whether it matters if they are cis or trans with respect to each other. If the solvent is changed
to acetone the preference for hydroxylation at tertiary carbon atoms is increased.
(iii) Epoxidation. Complexes containing two open coordination sites trans to each other are
the best choice for epoxidation. Acetonitrile is the solvent of choice to obtain the product
with good stereoselectivity.
(iv) Cis-dihydroxylation. Complexes containing two cis open coordination sites on the metal
are capable of stereoselective cis-dihydroxylation of olefins, especially when acetonitrile is
used as solvent. Epoxidation is usually found as side reaction with these catalysts, although it
appears that the ratio between these competing pathways can be controlled by proper choice
of the ligand. However, the precise requirements for ligand to achieve cis-dihydroxylation
exclusively are not clear to date.
(v) Trans-dihydroxylation. The catalysts used for cis-diydroxylation of olefins can also be
used to obtain trans-dihydroxylation. Only in the latter case acetone is needed as solvent.
Again epoxidation is found as competing reaction. Preliminary results indicate that trans-
dihydroxylation is limited to cis-alkenes. However, more substrates should be tested to assess
the validity of this hypothesis. At this point much is not clear about this trans-
dihydroxylation reaction. An unanswered question is whether the open coordination sites on
the metal have to be cis with respect to each other, or that trans location is also allowed.
Furthermore, it should be investigated whether this reaction is unique for acetone, or that
more solvents can be used.
These guidelines are only a rough indication how to obtain a certain type of chemistry. The
activity or stereoselectivity of the catalyst is usually controlled by the precise geometry of the
ligand, where small structural changes can have a profound effect.
8.6 DNA Cleavage
Complex 2 and derivatives were demonstrated to be very efficient catalysts for oxidative
DNA cleavage using O2, without the need of adding external reducing agents. Especially if a
DNA binding moiety, e.g. an acridine, was attached to the complex, instantaneous DNA
cleavage was observed.19 This concept of a DNA binding unit that can deliver a complex to
the DNA where it reacts to cause DNA cleavage can be further extended to get sequence
selective DNA cleavage. For this purpose the acridine unit has to be replaced by a moiety
than can recognize and bind to base pairs or a specific sequence of base pairs. That this
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approach is indeed viable was demonstrated by Dervan et al. who used distamycin24 and
hairpin polyamides25 to get selectivity in DNA cleavage. In view of the enormous amount of
information available on DNA recognition the possibilities for choosing the recognition
moiety are seemingly endless.26 Some obvious choices include small peptide chains,27
oligonucleotides,28 and metal complexes like cis-platinum,29 rhodium30 or zinc-cyclen
complexes.31 An extension of this approach would be the recognition of DNA bases or
sequences at a defined distance from each other. This can be accomplished by attaching two
DNA recognition groups to the N4Py ligand. The complex would then bind in between DNA
sequences at a distance equal to that of the combined spacer lengths. The advantage of this
approach is that smaller DNA recognition units can be used to achieve cleavage at a defined
position, compared to the case with one recognition moiety.
8.7 Prospects
In this final paragraph the prospects for non-heme iron complex as enzyme model and
oxidation catalyst are discussed. Non-heme iron complexes, and in particular N4Py-iron
complexes, have already proven their value as enzyme model.32 Continued study of these
complexes could lead to a better understanding of enzyme mechanisms and may lead to the
discovery and characterization of new iron-peroxo intermediates.
An exciting new area of research involves non-heme iron complexes as oxidation catalyst.
The first examples of complexes capable of stereoselective oxidation catalysts were described
in this thesis and in recent literature.22 Especially interesting are the stereoselective
hydroxylation of alkanes33 and cis-dihydroxylation of alkenes34 with H2O2, for which there
are not many alternatives. Epoxidation is also very useful in synthetic organic chemistry, but
it will be very difficult to rival the very efficient and highly enantioselective catalysts known
to date.35
Although this field of non-heme iron catalyzed stereoselective oxidations is still in its infancy
and these catalysts cannot be used on a preparative scale so far, these are very promising
developments. Undoubtedly the coming years will see the advent of a new generation of non-
heme iron catalysts that can be used as tool in synthetic organic chemistry.
A closely related topic is the design and synthesis of chiral catalysts capable of asymmetric
hydroxylation, epoxidation and cis and trans-dihydroxylation. Ligand design and screening
can possibly be done using combinatorial methods, as was demonstrated by Jacobsen and
coworkers, who have designed the first non-heme iron complex capable of enantioselective
epoxidation, albeit with a low ee.36
Finally, a promising new area of research will be O2 activation with non-heme iron
complexes. Non-heme iron oxygenases are capable of highly selective oxidation with the use
O2 as terminal oxidant.32 The challenge will be to achieve the same with model complexes,
with the ultimate goal to obtain iron catalysts that can perform selective oxidations of organic
substrates with O2 on a preparative scale. That model complexes are capable of O2 activation
was demonstrated in the DNA cleavage experiments (vide supra).
Looking at all these possibilities it is obvious that non-heme iron based oxidation catalysts
have a very bright future in front of them. Especially in view of their versatility, stability and
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relatively easy synthesis, an attractive conclusion is that non-heme iron complexes are the
oxidation catalysts of the future.
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